Please use this identifier to cite or link to this item:
Title: Why Is Rapamycin Not a Rapalog?
Authors: Kuerec, Ajla Hodzic 
Maier, Andrea B. 
Keywords: Sirolimus
Mammalian target of rapamycin inhibitors
Issue Date: 7-Jan-2023
Publisher: S. Karger AG
Citation: Kuerec, Ajla Hodzic, Maier, Andrea B. (2023-01-07). Why Is Rapamycin Not a Rapalog?. Gerontology. ScholarBank@NUS Repository.
Rights: Attribution-NonCommercial 4.0 International
Abstract: Rapamycin (sirolimus) is an immunosuppressive drug approved by the Food and Drug Administration (FDA). It is also a leading candidate for targeting aging. Rapamycin and its analogs (everolimus, temsirolimus, ridaforolimus) inhibit the mammalian target of rapamycin (mTOR) kinase by binding to FK506-binding proteins (FKBP) and have a similar chemical structure that only differs in the functional group present at carbon-40. Analogs of rapamycin were developed to improve its pharmacological properties, such as low oral bioavailability and a long half-life. The analogs of rapamycin are referred to as “rapalogs.” Rapamycin is the parent compound and should therewith not be called a “rapalog.”
Source Title: Gerontology
ISSN: 0304-324X
DOI: 10.1159/000528985
Rights: Attribution-NonCommercial 4.0 International
Appears in Collections:Elements
Staff Publications

Show full item record
Files in This Item:
File Description SizeFormatAccess SettingsVersion 
GER528985.pdf121.65 kBAdobe PDF



Google ScholarTM



This item is licensed under a Creative Commons License Creative Commons